Latest news
- Achievements06 March 2024
Adalvo Joins Medicines For Europe Association
Adalvo proudly announces its recent induction into Medicines for Europe, a renowned association advancing the generic pharmaceutical sector. As a member, Adalvo will play a pivotal role in shaping the future...
- Business01 March 2024
Adalvo Restarts Regulatory Procedures for Liraglutide DCP with Anticipated European Approval in June 2024
Adalvo is delighted to announce the restart of the DCP procedure for Liraglutide 6mg/ml pre-filled pen, with an estimated approval date anticipated in June 2024. As a generic and bioequivalent...
- Business29 February 2024
Adalvo Stands in Solidarity on Rare Disease Day
Adalvo stands in solidarity with the global community on Rare Disease Day, today February 29th, reminding us of the profound challenges faced by millions worldwide battling rare diseases, where access to...
- Business23 February 2024
Adalvo is among the first to register Mirabegron in European Markets
Adalvo is pleased to announce positive progress in the registration process for Mirabegron prolonged-release tablets in European markets. This product has been developed in collaboration with one of our strategic partners,...
- Business21 February 2024
Adalvo Leads the Way with First European Approval for Apremilast
Adalvo is pleased to announce that Apremilast 10mg, 20mg, and 30mg film-coated tablets has received its first approval in Europe. Having gained approval in December 2023, this positions Adalvo as the...
- Business13 February 2024
Adalvo announces successful European approval for Lisdexamfetamine Oral Solution
Adalvo is delighted to announce the successful DCP approval for Lisdexamfetamine Oral Solution 10mg/ml, developed in close collaboration with one of our strategic partners. This product represents a value-added version of Lisdexamfetamine...
- Business09 February 2024
Adalvo announces successful European approval for Nintedanib 100mg & 150mg Soft Gel Capsules
Adalvo is pleased to announce the successful DCP approval for Nintedanib 100mg & 150mg Soft Gel Capsules. This product is developed based on two distinguished reference brands, Ofev and Vargatef. Ofev is indicated for...
- Business07 February 2024
Adalvo Launches Desmopressin Sublingual Tablets in France
Adalvo is proud to announce the successful launch of Desmopressin Sublingual Tablets in France, solidifying our position as the first generic to introduce this innovative medication in the European Union. This accomplishment...
- Achievements05 February 2024
Adalvo Achieves Significant Milestone with 69 Marketing Authorisation Approvals in January 2024
Adalvo is delighted to announce a significant achievement for January 2024, securing a total of 69 Marketing Authorisation Approvals. This success spans across 18 countries, in collaboration with 12 esteemed strategic partners. During this...
- Business02 February 2024
Adalvo's Commitment To Oncology: Shaping a Brighter Future on World Cancer Day 2024
On World Cancer Day, Adalvo proudly stands at the forefront of the global battle against cancer. As we commemorate this significant day, we invite you to explore Adalvo's comprehensive Oncology...
- Business02 February 2024
Adalvo Commemorates World Cancer Day, Emphasising Commitment to Oncology
As World Cancer Day approaches on Sunday, February 4th, Adalvo reaffirms its commitment to making a meaningful impact in the fight against cancer. With a focus on oncology, Adalvo continues...
- Business22 January 2024
Adalvo Announces Successful DCP Submission for Brivaracetam Film-Coated Tablets
Adalvo is pleased to announce the successful DCP submission for Brivaracetam Film-Coated Tablets on Day 1 after the expiry of the Data Exclusivity period, developed in collaboration with one of...
- Business15 January 2024
Adalvo Announces Successful DCP Submission for Macitentan Film-Coated Tablets
Adalvo is pleased to announce the successful DCP submission for Macitentan 10mg film-coated tablets, developed in collaboration with one of our strategic partners. This product is based on the reference brand Opsumit 10mg film-coated...
- Achievements12 January 2024
Adalvo Successfully Implements SAP S/4HANA
Adalvo and ITP are thrilled to announce the successful implementation of SAP S/4HANA, marking the beginning of a promising journey in digital transformation. This collaboration has laid the foundation for a scalable cloud-based...
- Business27 December 2023
Adalvo announces successful DCP approval for Vortioxetine Film-Coated Tablets
Adalvo is pleased to announce the successful DCP approval for Vortioxetine Film-Coated Tablets. The product has been developed based on the reference brand Brintellix, which is indicated for treating major depressive episodes and sold...
- Business22 December 2023
Adalvo announces successful DCP approval of Pregabalin Prolonged Release Tablets
Adalvo is very proud to announce the successful DCP approval for Pregabalin Prolonged Release Tablets. Pregabalin Prolonged Release Tablets is a backbone medication indicated in the treatment of Neuropathic pain. Having a unique...
- Business18 December 2023
Adalvo Unaffected by EMA's Decision to Suspend Marketing Authorizations.
Reference is made to the recent notification issued by the European Medicines Agency on Friday, December 15th, recommending the suspension of more than 350generic medicines. The recommendation follows a Good...
- Business15 December 2023
Adalvo and Arphio Expand Access to Ambrisentan + Tadalafil Film Coated Tablets
Adalvo, in collaboration with Arphio, is proud to introduce Ambrisentan + Tadalafil Film-Coated Tablets (5mg+20mg, 5mg+40mg, 10mg+40mg), an innovative treatment addressing the urgent unmet needs of patients with Pulmonary Arterial Hypertension. In a phase...
- Business13 December 2023
Adalvo announces successful Pivotal BE Study for Empagliflozin/Metformin Tablets
Adalvo is pleased to announce that the Pivotal BE Study for Empagliflozin/Metformin Tablets 12.5/1000mg has been successfully completed. Our product has been developed based on the reference brand Synjardy 12.5mg/1000mg film-coated Tablets, which is indicated for...
- Business06 December 2023
Adalvo announces DCP approval for Apremilast film-coated tablets
We are pleased to announce the successful DCP approval for Apremilast 10mg, 20mg, 30mg film-coated tablets. Our product has been developed based on the reference brand Otezla Film-Coated Tablets, which is indicated in...
- Business01 December 2023
Adalvo announces successful Pivotal BE Study for Cladribine Tablets
Adalvo is pleased to announce that the successful Pivotal BE Study for Cladribine Tablets 10mg has been completed. Committed to innovation and a proactive market strategy, we are working towards becoming among...